Education
About Us
Working with TipRanks
Follow Us
GoodRx Holdings (GDRX)
NASDAQ:GDRX
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.09Last Year’s EPS
0.08Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -7.98%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reveals significant growth and achievements in consumer reach, pharmacy partnerships, and financial metrics, with a few notable challenges in subscription revenue and ISP program expansion.Company Guidance
During the GoodRx earnings call for the fourth quarter and full year 2024, the company provided guidance for 2025, expecting revenue to range between $810 million and $840 million, representing a growth of approximately 4% at the midpoint. The adjusted EBITDA is projected to be between $270 million and $286 million, indicating around 7% growth. In the fourth quarter of 2024, the company achieved revenue of $198.6 million and an adjusted EBITDA of $67.1 million, contributing to a full-year revenue of $792.3 million, up 6% year-over-year, and an adjusted EBITDA of $260.2 million, marking a 20% increase. The prescription transactions revenue grew 5% to $577.5 million, while subscription revenue declined by 8% to $86.5 million. The Pharma Manufacturer Solutions revenue saw a 26% increase, reaching $107.2 million. The company also noted improvements in pharmacy profitability, with a 20% increase per script in their partner pharmacies' book of business in January 2025 compared to the previous year. GoodRx highlighted the expansion of its integrated savings program and manufacturer solutions, aiming to enhance medication access and drive growth.Increased Consumer Use and Savings
In 2024, nearly 30 million consumers used GoodRx, which is almost 5 million more than in 2023, resulting in nearly $17 billion in medication savings.
Growth in Prescription Discount Segment
The share of the prescription discount segment grew by 3% year-over-year in the fourth quarter, reinforcing GoodRx's position as a leading platform for medication savings.
Pharmacy Partner Profitability
Partner pharmacies saw profitability increase by over 20% per script in January 2025 compared to the same period in 2024.
Manufacturer Solutions Revenue Growth
Pharma manufacturer solutions revenue increased by 26% year-over-year, growing the number of brands from 150 in 2023 to over 200 in 2024.
Financial Growth
Full year 2024 revenue was $792.3 million, up 6%, with adjusted EBITDA growing 20% year-over-year to $260.2 million.
---
GDRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GDRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $4.89 | $4.98 | +1.84% |
| Nov 07, 2024 | $6.11 | $5.04 | -17.51% |
| Aug 08, 2024 | $8.61 | $7.01 | -18.58% |
| May 09, 2024 | $7.61 | $6.93 | -8.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GoodRx Holdings (GDRX) report earnings?
GoodRx Holdings (GDRX) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is GoodRx Holdings (GDRX) earnings time?
GoodRx Holdings (GDRX) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GDRX EPS forecast?
GDRX EPS forecast for the fiscal quarter 2025 (Q1) is 0.09.
---
